Aegis Therapeutics has announced that the US Patent and Trademark Office has awarded the company US Patent No. 8,927,497, which covers a method “for non-invasive delivery of anti-seizure drugs via a simple metered nasal spray” based on the company’s Intravail transmucosal absorption enhancement technology. The patent, titled “Absorption enhancers for intranasal administration,” was issued January 9th.
The patent is the 21st for Aegis’s drug delivery technology, which the company has applied to a wide range of drugs for intranasal delivery. In November 2014, Aegis announced that it had received a patent for intranasal delivery of polypeptides to the central nervous system.
According to Aegis, it has submitted at least 50 more patent applications. The company licenses its formulations and in the past year has announced the availability of licenses for intranasal formulations of insulin and octreotide.
Read the Aegis Therapeutics press release.
